G. Clare Kahn, Ph.D.
Board Member
Stoke Therapeutics, Inc. (STOK)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About G. Clare Kahn, Ph.D.
G. Clare Kahn, Ph.D. is recorded as Board Member at Stoke Therapeutics, Inc. (STOK). Stoke Therapeutics, Inc. reported in an 8-K filed April 7, 2026 that G. Clare Kahn, Ph.D. was appointed Class I director, effective April 3, 2026.
“On April 3, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (“Stoke” or the “Company”), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective immediately, to fill the vacancy created by the increase in Board size.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-04-03–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Stoke Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Ian F. Smith CEO, Board Member
- Arthur Tzianabos Chairman
- Thomas E. Leggett CFO
- Thomas Leggett CFO
- Huw M. Nash COO
- Jonathan Allan General Counsel
- Alexander (Bo) Cumbo Board Member
- Garry Menzel, Ph.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.